- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07940192
Phenotype of Alcohol-Related Nutritional Sensory Neuronopathies and Comparison With Dysimmune and Paraneoplastic Forms (NNS-OH)
Sensory neuronopathies (SNNs) are rare disorders characterized by damage to sensory neurons in the dorsal root ganglia. They may have dysimmune, paraneoplastic, toxic, or genetic causes. Alcohol-related nutritional sensory neuronopathy has recently been described and may present acutely or subacutely with pain, mimicking dysimmune or paraneoplastic disease. Distinguishing these causes early may help guide appropriate management. This international, multicentre, retrospective observational cohort study will describe the initial and follow-up clinical and electrophysiological phenotype of acute/subacute alcohol-related nutritional SNN and compare it with dysimmune and paraneoplastic SNN. Data will be abstracted from existing medical records. The protocol anticipates approximately 75 participants with alcohol-related nutritional SNN, 50 with dysimmune SNN, and 20 with paraneoplastic SNN. No additional procedure is performed for research purposes and no direct benefit is expected for participants.
Studieöversikt
Status
Betingelser
Studietyp
Inskrivning (Beräknad)
Kontakter och platser
Studiekontakt
- Namn: Jean-Philippe CAMDESSANCHE, PUPH
- Telefonnummer: +33 04 77 12 78 05
- E-post: j.philippe.camdessanche@chuse.fr
Studieorter
-
-
-
Brest, Frankrike, 29200
- CHU de Brest
-
Kontakt:
- Jean-Baptiste NOURY
- Telefonnummer: +33 02 98 22 33 33
- E-post: jean-baptiste.noury@chu-brest.fr
-
Grenoble, Frankrike, 38500
- CHU de Grenoble
-
Kontakt:
- Martial Mallaret
- Telefonnummer: +33 04 76 76 75 75
- E-post: MMallaret1@chu-grenoble.fr
-
Lille, Frankrike, 59000
- CHU de Lille
-
Kontakt:
- Céline TARD, Dr
- Telefonnummer: +33 03 20 44 59 62
- E-post: CELINE.TARD@CHRU-LILLE.FR
-
Limoges, Frankrike, 87000
- CHU de Limoges
-
Kontakt:
- Laurent MAGY
- Telefonnummer: +33 05 55 05 55 55
- E-post: Laurent.Magy@chu-limoges.fr
-
Montpellier, Frankrike, 34090
- CHU de Montpellier
-
Kontakt:
- Guillaume TAIEB
- Telefonnummer: +33 04 67 33 67 33
- E-post: g-taieb@chu-montpellier.fr
-
Nantes, Frankrike, 44093
- CHU de Nantes
-
Kontakt:
- Yann PEREON
- Telefonnummer: +33 02 40 08 33 33
- E-post: Yann.Pereon@univ-nantes.fr
-
Reims, Frankrike, 51100
- CHU de REIMS
-
Kontakt:
- Maxime Kirchhofer, Dr
- Telefonnummer: +33 03 26 78 78 78.
- E-post: mkirchhofer@chu-reims.fr
-
-
France
-
Bordeaux, France, Frankrike, 33000
- CHU de Bordeaux
-
Kontakt:
- Guilhem SOLE, Dr
- Telefonnummer: +33 05.56.79.56.79
- E-post: guilhem.sole@chu-bordeaux.fr
-
Créteil, France, Frankrike, 94000
- CHU Henri-Mondor
-
Kontakt:
- Thierry GENDRE, Dr
- Telefonnummer: + 33 01 49 81 21 11
- E-post: thierry.gendre@aphp.fr
-
Garches, France, Frankrike, 92380
- AP-HP Hôpital Raymond-Poincaré
-
Kontakt:
- Edouard BERLING, Dr
- Telefonnummer: + 33 01 47 10 79 00
- E-post: edouard.berling@aphp.fr
-
Le Kremlin-Bicêtre, France, Frankrike, 94270
- CHU de Bicetre
-
Kontakt:
- Guillemette BEAUDONNET, Dr
- Telefonnummer: + 33 01 45 21 21 21
- E-post: guillemette.beaudonnet@aphp.fr
-
Marseille, France, Frankrike, 13005
- AP-HM Hôpital de la Timone
-
Kontakt:
- Emilien DELMONT, Dr
- Telefonnummer: +33 04 91 38 56 65
- E-post: Emilien.DELMONT@ap-hm.fr
-
Paris, France, Frankrike, 75013
- AP-HP Hôpital Pitié-Salpêtrière
-
Kontakt:
- Thierry MAISONOBE, Dr
- Telefonnummer: +33 01 42 16 00 00
- E-post: thierry.maisonobe@aphp.fr
-
Saint-Etienne, France, Frankrike, 42055
- CHU de Saint-Etienne
-
Kontakt:
- Jean-Philippe CAMDESSANCHE, PUPH
- Telefonnummer: + 33 04 77 12 78 05
- E-post: j.philippe.camdessanche@chuse.fr
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
Patients monitored in a neurology department for their sensory neuropathies
Beskrivning
Inclusion Criteria :
- Age ≥ 18 years.
- Probable sensory neuronopathy according to the diagnostic criteria of Camdessanché et al.
- Acute or subacute onset (0-6 months).
- One of the following aetiologies: Alcohol-related nutritional SNN: chronic alcohol misuse (>100 g/week for at least 3 months) and/or biological markers of alcohol consumption, with dysimmune and paraneoplastic causes excluded. The minimum work-up includes an immune laboratory assessment including serum anti-neuronal antibodies, lumbar puncture, and thoraco-abdominal imaging. Dysimmune SNN: associated with Sjögren's syndrome, lupus, primary biliary cholangitis, anti-FGFR3 antibodies, or anti-AGO antibodies. Paraneoplastic SNN: associated with anti-Hu or anti-CV2/CRMP5 antibodies.
Exclusion Criteria :
- Exposure to platinum salts before the onset of sensory neuronopathy.
- Known hereditary neuropathy.
- Patient under guardianship or curatorship (tutelle or curatelle).
- Patient objection to the use of their data for the study.
Studieplan
Hur är studien utformad?
Designdetaljer
- Observationsmodeller: COHORT
- Tidsperspektiv: RETROSPECTIVE
Kohorter och interventioner
Grupp / Kohort |
|---|
|
Alcohol-related nutritional sensory neuronopathy
Adults with probable acute/subacute SNN attributed to chronic alcohol misuse (>100 g ethanol/week for at least 3 months) and/or biological markers of alcohol consumption, with dysimmune and paraneoplastic causes excluded using the minimum work-up specified in the protocol. |
|
Dysimmune sensory neuronopathy
Adults with probable acute/subacute SNN attributed to Sjögren's syndrome, lupus, primary biliary cholangitis, or associated with anti-FGFR3 or anti-AGO antibodies. |
|
Paraneoplastic sensory neuronopathy
Adults with probable acute/subacute SNN associated with anti-Hu or anti-CV2/CRMP5 antibodies. |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Demographic and disease onset characteristics
Tidsram: from july 2006 to april 2027
|
Description of demographic characteristics and disease onset, including age at onset (years), mode of onset, and initial symptoms. Each variable will be reported individually, as available in the medical records. |
from july 2006 to april 2027
|
Samarbetspartners och utredare
Utredare
- Huvudutredare: Jean-Phillippe CAMDESSANCHE, PUPH, CHU de Saint-Etienne
Studieavstämningsdatum
Studera stora datum
Studiestart (Beräknad)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Andra studie-ID-nummer
- IRBN 154-2026/CHUSTE
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .